Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?

IF 5.3 2区医学 Q1 ONCOLOGY

Cancer Cell International Pub Date : 2024-10-27 DOI:10.1186/s12935-024-03525-9

Milad Taghizadeh Anvar, Kimiya Rashidan, Nima Arsam, Ashkan Rasouli-Saravani, Hamidreza Yadegari, Ali Ahmadi, Zeynab Asgari, Ahmad Ghorbani Vanan, Farid Ghorbaninezhad, Safa Tahmasebi

{"title":"Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?","authors":"Milad Taghizadeh Anvar, Kimiya Rashidan, Nima Arsam, Ashkan Rasouli-Saravani, Hamidreza Yadegari, Ali Ahmadi, Zeynab Asgari, Ahmad Ghorbani Vanan, Farid Ghorbaninezhad, Safa Tahmasebi","doi":"10.1186/s12935-024-03525-9","DOIUrl":null,"url":null,"abstract":"<p><p>T helper (Th) 17 cells, a distinct subset of Th lymphocytes, are known for their prominent interleukin (IL)-17 production and other pro-inflammatory cytokines. These cells exhibit remarkable plasticity, allowing them to exhibit different phenotypes in the cancer microenvironment. This adaptability enables Th17 cells to promote tumor progression by immunosuppressive activities and angiogenesis, but also mediate anti-tumor immune responses through employing immune cells in tumor setting or even by directly converting toward Th1 phenotype and producing interferon-gamma (IFN-γ). This dual role of Th17 cells in cancer makes it a double-edged sword in encountering cancer. In this review, we aim to elucidate the complexities of Th17 cell function in cancer by summarizing recent studies and, ultimately, to design novel therapeutic strategies, especially targeting Th17 cells in the tumor milieu, which could pave the way for more effective cancer treatments.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"24 1","pages":"355"},"PeriodicalIF":5.3000,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514949/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-024-03525-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

T helper (Th) 17 cells, a distinct subset of Th lymphocytes, are known for their prominent interleukin (IL)-17 production and other pro-inflammatory cytokines. These cells exhibit remarkable plasticity, allowing them to exhibit different phenotypes in the cancer microenvironment. This adaptability enables Th17 cells to promote tumor progression by immunosuppressive activities and angiogenesis, but also mediate anti-tumor immune responses through employing immune cells in tumor setting or even by directly converting toward Th1 phenotype and producing interferon-gamma (IFN-γ). This dual role of Th17 cells in cancer makes it a double-edged sword in encountering cancer. In this review, we aim to elucidate the complexities of Th17 cell function in cancer by summarizing recent studies and, ultimately, to design novel therapeutic strategies, especially targeting Th17 cells in the tumor milieu, which could pave the way for more effective cancer treatments.

查看原文本刊更多论文

癌症中的 Th17 细胞功能：免疫抑制剂还是抗肿瘤盟友？

T辅助（Th）17细胞是Th淋巴细胞的一个独特亚群，因其突出的白细胞介素（IL）-17和其他促炎细胞因子分泌而闻名。这些细胞具有显著的可塑性，能在癌症微环境中表现出不同的表型。这种适应性使 Th17 细胞既能通过免疫抑制活动和血管生成促进肿瘤进展，又能通过在肿瘤环境中利用免疫细胞或甚至直接向 Th1 表型转化并产生干扰素-γ（IFN-γ）来介导抗肿瘤免疫反应。Th17 细胞在癌症中的这种双重作用使其成为对付癌症的一把双刃剑。在这篇综述中，我们旨在通过总结最近的研究阐明 Th17 细胞在癌症中功能的复杂性，并最终设计出新型治疗策略，尤其是针对肿瘤环境中的 Th17 细胞，从而为更有效的癌症治疗铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.